Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 12/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12322203 | 0.86 | CYP2D6 (0.51) | CYP2D6FAAHKDM4EL3MBTL1HPGD | |
| SCHEMBL11268852 | 0.86 | CYP2D6 (0.51) | CYP2D6FAAHKDM4EL3MBTL1HPGD | |
| SCHEMBL12322194 | 0.86 | HRH4 (0.54) | CYP2D6FAAHKDM4EL3MBTL1AOC3 | |
| SCHEMBL11280431 | 0.82 | FAAH (0.49) | CYP2D6FAAHKDM4EL3MBTL1HTT | |
| SCHEMBL12322218 | 0.82 | FAAH (0.49) | CYP2D6FAAHKDM4EL3MBTL1HTT | |
| SCHEMBL6300841 | 0.80 | KDM4E (0.50) | CYP2D6FAAHKDM4EL3MBTL1HPGD | |
| SCHEMBL3403712 | 0.79 | FAAH (0.68) | CYP2D6FAAH | |
| SCHEMBL4726854 | 0.79 | CYP2D6 (0.61) | CYP2D6FAAHKDM4EL3MBTL1HPGD | |
| SCHEMBL14292081 | 0.79 | CYP2D6 (0.61) | CYP2D6FAAHKDM4EL3MBTL1HPGD | |
| SCHEMBL3406721 | 0.79 | FAAH (0.68) | CYP2D6FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159437-A1 | Pharmaceutical agents | JARROTT BEVYN (AU) | 2005-07-21 | — | — | US | disclosed |
| US-6881740-B1 | Pharmaceutical agents | MONASH UNIVERSITY (AU) | 2005-04-19 | — | — | US | disclosed |
| EP-1095026-A4 | PHARMACEUTICAL AGENTS | UNIV MONASH (AU) | 2001-10-31 | — | — | EP | disclosed |
| EP-1095026-A1 | PHARMACEUTICAL AGENTS | MONASH UNIVERSITY (AU) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000002865-A1 | PHARMACEUTICAL AGENTS | MONASH UNIVERSITY (AU) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159437-A1 | Pharmaceutical agents | F12, NAT1, H1-0 | CYP2D6 35/4885FAAH 295/4885KDM4E 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.